BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ ( Bicycle TICA™) induces tumor localized CD137 agonism.

Kristen HurovJohanna LahdenrantaPunit UpadhyayaEric HainesHeather CohenElizabeth RepashDrasti KanakiaJun MaJulia KristenssonFanglei YouCarly CampbellDavid WittyMike KellyStephen BlakemorePhil JeffreyKevin McDonnellPhilip BrandishNicholas Keen

Published in: Journal for immunotherapy of cancer (2022)

BT7480 is a highly potent Nectin-4-dependent CD137 agonist that produces complete regressions and antitumor immunity with only intermittent drug exposure in syngeneic mouse tumor models and is well tolerated in preclinical safety species. This work supports the clinical investigation of BT7480 for the treatment of cancer in humans.

Keyphrases

papillary thyroid
squamous cell carcinoma
bone marrow
high intensity
nk cells
drug delivery
combination therapy
smoking cessation